Nicotine Salts vs. Freebase: Which Specification Actually Sells in the EU and UK — and Why Your OEM Factory Needs to Know the Difference

By David Chen, Factory Director, GG-VAPE

This is not a consumer guide about which nicotine type “feels better.” If you’re a brand owner or wholesale buyer sourcing OEM hardware for European markets, the nicotine specification question has commercial and regulatory implications that go well beyond smoothness vs. throat hit.

Getting this wrong in your product brief costs you margin, slows your EU-CEG notification, and can result in a product that technically complies with TPD but doesn’t move off retail shelves because it doesn’t satisfy what European consumers in your target segment actually want in 2026.

Here’s the decision framework.

What the Chemistry Actually Means for Product Development

Freebase nicotine is the standard form — chemically unmodified, higher pH, detectable throat hit at concentrations above roughly 12mg/ml. It was the industry default in the early pod era and still dominates sub-ohm hardware categories where lower nicotine concentrations work with the higher vapor volume.

Nicotine salts are freebase nicotine combined with an acid — most commonly benzoic acid — which lowers the pH and changes the delivery profile. The practical result: smoother throat sensation at higher nicotine concentrations, faster absorption, and a satisfaction curve that more closely resembles combustible cigarettes. For closed pod systems and low-output hardware, this matters because those devices don’t produce the vapor volume that makes freebase satisfying at 3–6mg/ml.

The chemistry difference becomes a product decision when you map it to your hardware specification:

The EU/UK Market Reality in 2026

The EU TPD ceiling of 20mg/ml applies to both nicotine types equally. But the behavioral difference between the two at that ceiling is significant, and it shapes what actually sells in each product category.

For closed pod systems — which dominate the EU convenience and pharmacy retail channel — nicotine salt at 10–20mg/ml is the standard specification. The device wattage is low, vapor volume is moderate, and satisfaction depends on nicotine delivery efficiency rather than cloud production. Freebase at the same concentration in this hardware produces an uncomfortable throat hit that drives consumer returns and negative reviews.

For refillable open pod systems and sub-ohm hardware targeting experienced vapers — smaller but persistent segments in Germany, Netherlands, and Scandinavia — freebase at 3–6mg/ml remains the appropriate specification.

The practical implication for OEM briefs: if you are developing a closed pod system for EU retail, specify nicotine salt formulation in your product brief from day one. Your OEM factory’s e-liquid partner needs to know this before they begin development — the benzoic acid concentration and formulation approach affects both the hardware coil specification and the emissions testing outcomes.

Why This Affects Your TPD Notification — Not Just Your Flavor Brief

The nicotine specification in your product determines what your EU-CEG notification must include, and the two types have different technical documentation requirements.

Nicotine salt formulations require declaration of the acid compound used (benzoic acid being most common), its concentration, and its role in the formulation. UK MHRA’s TRPR, as updated in 2026, requires more detailed nicotine salt compound declarations than the EU-CEG system — a meaningful divergence for brands running parallel EU and UK registrations.

If your OEM factory is developing your e-liquid formulation, they need to provide the full ingredient list including the salt formation compounds in a format compatible with both submission systems. Factories that have not previously submitted nicotine salt products to EU-CEG sometimes provide ingredient lists structured for Chinese regulatory formats that don’t map cleanly onto the ECID data fields. This adds weeks to a notification process that already takes six months.

Specify upfront: “We need EU-CEG and UK TRPR compatible ingredient documentation for a nicotine salt formulation.” That single line in your brief filters out suppliers who haven’t done this before.

Synthetic Nicotine: The 2026 Consideration

A growing number of EU market brands are evaluating synthetic nicotine — tobacco-free nicotine (TFN) produced through chemical synthesis rather than tobacco extraction — for specific product lines.

The regulatory picture is still developing. Synthetic nicotine is not inherently exempt from TPD/TRPR requirements in the EU and UK — regulatory interpretation has moved toward treating the nicotine content as the determining factor, not the source. Before building a product strategy around synthetic nicotine for European markets, verify the current regulatory position with a compliance specialist in your target market.

Where synthetic nicotine has genuine traction in 2026 is in markets outside the EU/UK where the regulatory framework explicitly excludes tobacco-derived products, and in premium brand positioning where “tobacco-free” is a meaningful marketing claim to a specific consumer segment. If that’s your target, the formulation and documentation requirements are different and need to be built into your OEM brief from the start.

The Brief Your Factory Needs From You

Most nicotine specification problems in OEM production come from a brief that says “nicotine salt, 20mg” without specifying the downstream requirements. A complete nicotine specification brief for EU/UK OEM covers:

• Nicotine type (freebase / nicotine salt / synthetic)
• Target concentration and acceptable range
• Target throat hit profile (smooth / moderate / pronounced)
• Target absorption speed (relevant to consumer transition from combustibles)
• Hardware this formulation will be paired with (device wattage, coil resistance, airflow)
• Destination markets and which regulatory submission systems apply
• Whether EU-CEG and UK TRPR compatible ingredient documentation is required

Factories that can’t respond to this brief with specific technical answers — not just “yes we can do that” — are not set up to support compliant European product development.

Where This Fits in Your OEM Decision

Nicotine specification is one input into a broader product development brief. It interacts with your hardware choice, your compliance timeline, your target consumer profile, and the retail channel you’re aiming for.

If you’re building a closed pod system for EU convenience retail, the answer is nicotine salt at 18–20mg/ml and you need a factory that can produce compliant e-liquid documentation for that formulation. That decision should be in your brief before you request samples.

If you’re building a refillable sub-ohm product for specialist vape retail, freebase at 3–6mg/ml is the conventional specification and the documentation path is more straightforward.

If you’re uncertain which product category is right for your target market, that’s a brand strategy question worth resolving before you spend money on samples.

Discuss your product specification with the GG-VAPE team → View OEM/ODM Services →

🔗 Related Reading

• EU & UK Vape Compliance 2026: TPD, EPR and OEM Guide
• How to Choose a Vape OEM Manufacturer: The Complete Guide
• The Rise of Synthetic Nicotine in Regulated Markets

For B2B trade enquiries only. Adults 18+ only.